Abstract
The most popular drugs for treating HER2 positive breast cancer are Trastuzumab or lapatinib. Clinical trials in recent years have begun where the two drugs are now being used in combination. Some of the trial results appear to be promising and the combination therapy could provide a new way in which to combat resistance to therapies and improve disease free survival compared to when either drug is used alone. This article describes the benefit of targeting HER2 positive breast cancer with multiple therapies and proposes a novel way in which to treat the disease; to add an ADAM10 inhibitor to the Trastuzumab and lapatinib combination.
Highlights
20-30% of all breast cancer cases are HER2 positive [1]
HER2 or human epidermal growth factor 2, is a receptor expressed on the cell surface of breast cells and in normal situations is important for proper maintenance and cell growth [2]
In two other trials, women who had early stage HER2 positive breast cancer who had no previous treatments, were given Trastuzumab, lapatinib, or the combination of drugs followed by cytotoxic regimens
Summary
20-30% of all breast cancer cases are HER2 positive [1]. HER2 or human epidermal growth factor 2, is a receptor expressed on the cell surface of breast cells and in normal situations is important for proper maintenance and cell growth [2]. Lapatinib is an approved drug for HER2 positive breast cancer but it targets the HER2 in a very different way than Trastuzumab [9,10].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
